ANRO — Alto Neuroscience, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1999480 ·
Last close
$21.06
Market Cap
$739.08M
52W High
$28.44
52W Low
$18.56
ADV30
322,749
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,138,000 | -26,237,000 | 276,259,000 | 263,762,000 | 32,890,000 |
| Dec 2025 | 0 | — | -17,055,000 | -16,182,000 | 184,689,000 | 176,484,000 | 33,547,000 |
| Sep 2025 | 0 | — | -14,951,000 | -14,181,000 | 147,006,000 | 137,816,000 | 35,449,000 |
| Jun 2025 | 0 | — | -18,682,000 | -17,706,000 | 157,877,000 | 147,585,000 | 34,465,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-51,769,000
Investing CF
$-24,000
Financing CF
$60,078,000
CapEx
$-1,535,000
Dividends Paid
—
Buybacks
$100,000
EPS Diluted TTM
$-2.35
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-201,634,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-60,769,000
Pretax Income TTM
$-63,238,000
Interest Exp TTM
$2,469,000
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -66,364,000 | -63,238,000 | 184,689,000 | 33,547,000 | — | -51,769,000 |
| Dec 2024 | 0 | -68,610,000 | -61,431,000 | 177,542,000 | 26,082,000 | — | -47,424,000 |
| Dec 2023 | 0 | -37,809,000 | -36,305,000 | 86,628,000 | 158,300,000 | — | -33,448,000 |
| Dec 2022 | 0 | -27,455,000 | -27,710,000 | 50,854,000 | 89,260,000 | — | -20,394,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$3,214,000
NetIncome TTM
$-25,924,000
OpCashFlow TTM
$0
Assets (Latest)
$177,542,000
Forward EPS
$-3.24
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $21.06 · call volume: 172 · put volume: 65
Expected Move to 2026-07-17:
±$8.02
(38.08%) —
implied range
$13.04 –
$29.08
· ATM straddle on $20.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RLMD | RELMADA THERAPEUTICS, INC. | $752.06M | $7.17 | — |
| BIOA | BioAge Labs, Inc. | $720.13M | $16.20 | — |
| DSGN | Design Therapeutics, Inc. | $712.01M | $11.40 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $709.59M | $33.68 | — |
| CYRX | Cryoport, Inc. | $703.62M | $13.96 | — |
News headlines (Yahoo Finance, 1h cache)
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
2026-05-15 12:27 · Yahoo
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 11:03 · Yahoo
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
2026-05-11 20:05 · Yahoo
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
2026-05-04 12:03 · Yahoo
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
2026-04-21 12:03 · Yahoo
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
2026-04-02 20:10 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-04-02 19:57 · Yahoo
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
2026-04-02 18:36 · Yahoo
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
2026-04-02 12:20 · Yahoo
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
2026-04-01 20:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.